Moderna (MRNA) Common Equity (2017 - 2026)
Moderna (MRNA) posted quarterly Common Equity of $6.8 billion for Q2 2026, down 28.07% year-over-year from $9.4 billion in Q2 2025, and down 8.73% on a QoQ basis from $7.4 billion in Q1 2026.
Moderna (MRNA) Common Equity (2017 - 2026) Analysis & Trends
Moderna has reported Common Equity for 10 years, with the latest figure at $6.8 billion in Q2 2026.
- Common Equity for Q2 2026 came in at $6.8 billion, down 28.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $6.8 billion (down 28.07% YoY), and the FY2025 annual result was $8.6 billion, down 20.65% from the prior year.
- Common Equity slipped to $6.8 billion in Q2 2026, from $7.4 billion in the prior quarter.
- Over five years, Common Equity peaked at $19.1 billion in Q4 2022 and troughed at $6.8 billion in Q2 2026.
- A 5-year average of $13.0 billion and a median of $12.4 billion in 2024 frame the typical range for Common Equity.
- The widest annual swing landed in 2022, when Common Equity surged 344.89%; it then slumped 32.05% in 2024.
- A 5-year view of Common Equity shows it stood at $19.1 billion in 2022, then dropped by 27.55% to $13.9 billion in 2023, then slipped by 21.32% to $10.9 billion in 2024, then declined by 20.65% to $8.6 billion in 2025, then declined by 21.84% to $6.8 billion in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $6.8 billion in Q2 2026, $7.4 billion in Q1 2026, and $8.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 6.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.76 Bn |
| Mar 31, 2026 | 7.41 Bn |
| Dec 31, 2025 | 8.65 Bn |
| Sep 30, 2025 | 9.33 Bn |
| Jun 30, 2025 | 9.40 Bn |
| Mar 31, 2025 | 10.07 Bn |
| Dec 31, 2024 | 10.90 Bn |
| Sep 30, 2024 | 11.93 Bn |
| Jun 30, 2024 | 11.71 Bn |
| Mar 31, 2024 | 12.82 Bn |
| Dec 31, 2023 | 13.85 Bn |
| Sep 30, 2023 | 13.46 Bn |
| Jun 30, 2023 | 16.95 Bn |
| Mar 31, 2023 | 18.86 Bn |
| Dec 31, 2022 | 19.12 Bn |
| Sep 30, 2022 | 17.99 Bn |
| Jun 30, 2022 | 17.99 Bn |
| Mar 31, 2022 | 17.08 Bn |
| Dec 31, 2021 | 14.15 Bn |
| Sep 30, 2021 | 10.12 Bn |